Arrhythmias & electrophysiology
Effect of antihypertensive agents on the risk of new-onset and recurrent atrial fibrillation: a Bayesian network meta-analysis of randomized controlled trials
Authors' conclusion
In this NMA comparing multiple antihypertensive regimens in patients with hypertension, diabetes, or AF, ACE inhibitors plus TD, ACE inhibitors, and ARBs were the most effective in reducing AF events, outperforming CCBs.
Study context
- Population
- Patients with hypertension, DM or atrial fibrillation (AF)
- Participants
- 66,156 patients · 22 randomized controlled trials (RCTs)
- Comparison
- Antihypertensive agents vs each other
- Outcome
- New-onset or recurrent AF
Methodological detailsrandom-effects, surface under the cumulative ranking (SUCRA) ranking
- Random-effects
- SUCRA ranking
Pooled result
As reported in the abstract
New-onset or recurrent AF
ACEi plus TD
0.86
SUCRA
Angiotensin receptor blockers (ARBs)
0.77
SUCRA
Mineralocorticoid antagonists (MRAs)
0.75
SUCRA
ACEi
0.53
SUCRA
Each group vs CCBsRelative risk (95% CrI)
ACEi plus TD
0.44(0.23–0.82)
ACEi
0.66(0.44–0.95)
ARBs
0.52(0.38–0.70)
Further pooled results
Secondary and sensitivity analyses
- Findings consistent across secondary and sensitivity analyses
Original publication
Effect of antihypertensive agents on the risk of new-onset and recurrent atrial fibrillation: a Bayesian network meta-analysis of randomized controlled trials. Eur J Prev Cardiol. Published 1 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it